文献速递精神分裂症与精神病性障碍

听觉oddball刺激的P300反应与精神病风险综合征临床结局的关联

Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

基于北美前驱期纵向研究(NAPLS-2)的多中心病例对照数据,比较552例精神病风险综合征(PRS)个体与236名健康对照的听觉P300波幅。结果显示PRS组靶刺激P3b及新奇刺激P3a波幅均降低,且靶刺激P3b在转化为精神病者中进一步降低,并与更短转化时间相关;缓解者基线靶P3b波幅与健康对照相似。

要点

  • PRS个体靶刺激P3b和新奇刺激P3a波幅较健康对照降低(d=0.37)。
  • 靶刺激P3b在精神病转化者中较未转化者降低(d=0.26),且波幅越小转化时间越短(HR=1.45)。
  • PRS缓解者基线靶P3b波幅与健康对照相似,且高于转化者(d=0.51)和持续症状者(d=0.41)。

核心结论

  • P300波幅缺陷可能先于精神病发作出现。
  • 靶刺激P3b波幅对PRS的临床结局(包括转化为精神病和临床缓解)可能敏感。
  • 听觉靶刺激P3b波幅有望作为PRS临床结局的预后生物标志物。

研究设计与样本

  • 多中心病例对照研究,数据来自北美前驱期纵向研究(NAPLS-2)的8个大学附属门诊项目。
  • 纳入552例符合PRS标准的个体和236名健康对照,均有P300数据。
  • 比较转化为精神病者(n=73)、随访24个月仍持续症状的未转化者(n=135)和从PRS缓解者(n=90)的基线听觉P300数据。

主要发现

  • PRS组(n=552,女性236例占42.8%,平均年龄19.21岁,SD=4.38)与健康对照组(n=236,女性111例占47.0%,平均年龄20.44岁,SD=4.73)相比,靶刺激P3b和新奇刺激P3a波幅降低(d=0.37)。
  • 精神病转化者与非转化者相比,靶刺激P3b波幅显著降低(d=0.26),但新奇刺激P3a无显著差异。
  • 在PRS个体中,靶刺激P3b波幅越小与精神病发作时间越短相关(风险比1.45;95%CI 1.04-2.00;P=.03)。
  • PRS缓解者基线靶刺激P3b波幅与健康对照相似,且高于转化者(d=0.51)和持续症状的PRS个体(d=0.41)。

临床怎么用

  • 听觉靶刺激P3b波幅可作为PRS个体临床结局的候选预后生物标志物,辅助评估转化风险和缓解可能性。
  • 基线靶刺激P3b波幅降低可能提示更短的精神病转化时间,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In most patients, a prodromal period precedes the onset of schizophrenia. Although clinical criteria for identifying the psychosis risk syndrome (PRS) show promising predictive validity, assessment of neurophysiologic abnormalities in at-risk individuals may improve clinical prediction and clarify the pathogenesis of schizophrenia. OBJECTIVE: To determine whether P300 event-related potential amplitude, which is deficient in schizophrenia, is reduced in the PRS and associated with clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: Auditory P300 data were collected as part of the multisite, case-control North American Prodrome Longitudinal Study (NAPLS-2) at 8 university-based outpatient programs. Participants included 552 individuals meeting PRS criteria and 236 healthy controls with P300 data. Auditory P300 data of participants at risk who converted to psychosis (n = 73) were compared with those of nonconverters who were followed up for 24 months and continued to be symptomatic (n = 135) or remitted from the PRS (n = 90). Data were collected from May 27, 2009, to September 17, 2014, and were analyzed from December 3, 2015, to May 1, 2019. MAIN OUTCOMES AND MEASURES: Baseline electroencephalography was recorded during an auditory oddball task. Two P300 subcomponents were measured: P3b, elicited by infrequent target stimuli, and P3a, elicited by infrequent nontarget novel stimuli. RESULTS: This study included 788 participants. The PRS group (n = 552) included 236 females (42.8%) (mean [SD] age, 19.21 [4.38] years), and the healthy control group (n = 236) included 111 females (47.0%) (mean [SD] age, 20.44 [4.73] years). Target P3b and novelty P3a amplitudes were reduced in at-risk individuals vs healthy controls (d = 0.37). Target P3b, but not novelty P3a, was significantly reduced in psychosis converters vs nonconverters (d = 0.26), and smaller target P3b amplitude was associated with a shorter time to psychosis onset in at-risk individuals (hazard ratio, 1.45; 95% CI, 1.04-2.00; P = .03). Participants with the PRS who remitted had baseline target P3b amplitudes that were similar to those of healthy controls and greater than those of converters (d = 0.51) and at-risk individuals who remained symptomatic (d = 0.41). CONCLUSIONS AND RELEVANCE: In this study, deficits in P300 amplitude appeared to precede psychosis onset. Target P3b amplitudes, in particular, may be sensitive to clinical outcomes in the PRS, including both conversion to psychosis and clinical remission. Auditory target P3b amplitude shows promise as a putative prognostic biomarker of clinical outcome in the PRS.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hamilton HK, Roach BJ, Bachman PM, et al. Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. JAMA Psychiatry. 2019. PMID: 31389974. doi:10.1001/jamapsychiatry.2019.2135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。